Adalvo and Gebro Pharma announce the successful launch of Pregabalin Prolonged Release Tablets in Spain, under the brand Dalingo®.
This product, indicated for treating Neuropathic Pain, is set to enhance patient adherence through its unique prolonged-release formulation. Pregabalin Prolonged Release Tablets offer a distinctive advantage by reducing the daily administration requirements, addressing a crucial aspect of patient convenience and treatment compliance.
"With the launch of Pregabalin Prolonged Release Tablets, we are not only providing a differentiated solution but also strengthening our partnership with Gebro Pharma," notes Anil Okay, Adalvo CEO. "Our combined expertise ensures that we will bring effective and convenient treatment options to the market."
"We believe that Pregabalin Prolonged Release Tablets will make a meaningful difference in the lives of patients," states Gustavo Pérez, Gebro Pharma Chief Commercial Officer. "By offering a convenient and effective treatment option, we are helping to meet the needs of patients suffering from Neuropathic Pain."
With a global annual sales figure of $2065Mn in 2023, as reported by IQVIA, Pregabalin products have demonstrated significant market impact, underscoring the immense potential of this product.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.
With headquarters in Malta, the company has additional offices in more than 17 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and designed to challenge the status quo: together, this helps our partners achieve their business goals.
We take pride in our ability to help our partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.
The company’s purpose-driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
About Gebro Pharma
Laboratorios Gebro Pharma is a pharmaceutical company dedicated to the development and commercialization of prescription and hospital medicines. Established in Spain since 2002 and headquartered in Barcelona, the company currently employs 150 people in our country. It is part of the Austrian pharmaceutical group Gebro Pharma GmbH, which has been engaged in research, manufacturing, and marketing of pharmaceutical specialities for over 75 years.
In our country, the company is a reference and develops and markets a portfolio of leading drugs in the areas of autoimmune diseases, pain, urology, respiratory, and dermatology.
In 2020, it received the Great Place to Work certification as an excellent place to work, and in 2021, it was ranked as one of the 'Best Places to Work in Spain' among the top 25 companies with the Best Place to Work 2021 certification.https://gebro.es/
Disclaimer: Products which are subject to patent protection is currently not offered or made available in countries where patents are in force.